2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Aldose Reductase

Aldose Reductase

Aldose Reductase

Related Products

PDF 0.43 MB

Aldose reductase is a small, cytosolic, monomeric enzyme which belongs to the aldo-keto reductase superfamily. Aldose reductase catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds. It is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney.

Aldose reductase is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Aldose reductase represents an excellent drug target and a huge effort is being done to disclose novel compounds able to inhibit it.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-152188
    AKR1C3-IN-9
    		Inhibitor 99.77%
    AKR1C3-IN-9 is a selective inhibitor of Aldo-keto Reductase 1C3 (AKR1C3) with an IC50 value of 8.92 nM. AKR1C3-IN-9 significantly reverses the Doxorubicin (HY-15142A) (DOX) resistance in a resistant breast cancer cell line.
    AKR1C3-IN-9
  • HY-118819
    5-Bromo-3-phenyl salicylic acid
    		Inhibitor 98.00%
    5-Bromo-3-phenyl salicylic acid is a selective inhibitor for human 20α-hydroxysteroid dehydrogenase (AKR1C1) with Ki of 140 nM.
    5-Bromo-3-phenyl salicylic acid
  • HY-B1202
    Alrestatin
    		Inhibitor 99.67%
    Alrestatin (AY-22284) is an aldose reductase inhibitor. Alrestatin reduces fructose levels in the uterine fluid of mice. Alrestatin interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin can be used in studies related to diabetes and reproductive diseases.
    Alrestatin
  • HY-163940
    LX1
    		Inhibitor 99.13%
    LX1 is an anti-prostate cancer compound that targets androgen receptor (AR), AR variants and steroidogenic enzyme AKR1C3. LX1 inhibits the enzymatic activity of AKR1C3, reduces the conversion of androstenedione to testosterone and reduces the expression of AR and AR-V7 and downregulates their target genes. LX1 overcomes the resistance of tumor cells to Enzalutamide (HY-70002), and the combination with Enzalutamide (HY-70002) further inhibits tumor growth.
    LX1
  • HY-171115
    Pyrone-211
    		Inhibitor 99.32%
    Pyrone-211 is a potent GPR84 agonist and AKR1C3 inhibitor. Pyrone-211 participates in an expanded polyamine pathway.
    Pyrone-211
  • HY-N7962
    Cornoside
    		Inhibitor
    Cornoside is a phenolic glycoside and has inhibitory effect on rat lens aldose reductase (AR) with an IC50 of 150 μM.
    Cornoside
  • HY-131586
    3,7-Dihydroxyflavone
    		Inhibitor 98.04%
    3,7-Dihydroxyflavone (Resogalangin) is a flavonoid phytoestrogen, which can be isolated from Adenophora species. 3,7-Dihydroxyflavone is a modulator of estrogen receptors and an inhibitor of human progesterone metabolizing enzyme AKR1C1 and fungal 17β-hydroxysteroid dehydrogenase and a redox inhibitor (IC50=0.6 and 6.0 μM, respectively). 3,7-Dihydroxyflavone is a fluorescent binding substrate for human serum albumin (HSA) with excitation wavelengths of 370 nm (pH 7.4) and 350 nm (pH 3.5), respectively, and emission wavelength of 515 nm.
    3,7-Dihydroxyflavone
  • HY-116170
    SN34037
    		99.02%
    SN34037 is a specific inhibitor of Aldo-keto reductase 1C3 (AKR1C3, EC 1.1.1.188) with the ability to inhibit the cytotoxic activity of PR-104A. SN34037-sensitive coumberone reduction provides a rapid and specific assay for AKR1C3 activity. SN34037 inhibits the aerobic cytotoxicity of PR-104A in TF1 erythroleukemia cells with high AKR1C3 expression, but not in Nalm6 pre-B acute lymphoblastic leukemia cells with low AKR1C3 expression.
    SN34037
  • HY-176084
    RJG-2051
    		Inhibitor 99.42%
    RJG-2051 is a selective covalent aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with an IC50 value of 13 nM. RJG-2051 interferes with the metabolic process of substrates such as androgens, estrogens, and prostaglandins by AKR1C3. RJG-2051 is promising for research of cancers.
    RJG-2051
  • HY-150630
    ALR2-IN-1
    		Inhibitor 99.33%
    ALR2-IN-1 is a potent and selective ALR2 inhibitor (IC50=1.42 μM). ALR2-IN-1 shows antioxidant and antiglycative properties. ALR2-IN-1 can be used in diabetic complication research.
    ALR2-IN-1
  • HY-16500R
    Tolrestat (Standard)
    		Inhibitor
    Tolrestat (Standard) is the analytical standard of Tolrestat. This product is intended for research and analytical applications. Tolrestat is a potent, orally active aldose reductase inhibitor with IC50 of 35 nM.
    Tolrestat (Standard)
  • HY-66009R
    Epalrestat (Standard)
    		Inhibitor
    Epalrestat (Standard) is the analytical standard of Epalrestat. This product is intended for research and analytical applications. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy.
    Epalrestat (Standard)
  • HY-16433
    Risarestat
    		Inhibitor 98.03%
    Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications.
    Risarestat
  • HY-N13759
    Mumeose K
    		Inhibitor
    Mumeose K is the inhibitor for aldose reductase with an IC50 of 27 μM. Mumeose K exhibits potential anti-diabetic activity, and can be used in research about diabetes-related complication.
    Mumeose K
  • HY-N1517R
    Ganoderic acid C2 (Standard)
    Ganoderic acid C2 (Standard) is the analytical standard of Ganoderic acid C2. This product is intended for research and analytical applications. Ganoderic acid C2 is a bioactive triterpenoid in Ganoderma lucidum. Ganoderic acid C2 possesses the potential anti-tumor bioactivity, antihistamine, anti-aging and cytotoxic effects. Ganoderic acid C2 is the inhibitor for aldose reductase with an IC50 of 43.8 µM.
    Ganoderic acid C2 (Standard)
  • HY-176719
    AKR1B1/STAT3/SLC7A11-regulator-1
    		Inhibitor
    AKR1B1/STAT3/SLC7A11-regulator-1 (5a) is an AKR1B1/STAT3/SLC7A11 regulator that reverses DOX resistance in MCF-7/ADR cells by enhancing ferroptosis activity. AKR1B1/STAT3/SLC7A11-regulator-1 can be used in breast cancer research.
    AKR1B1/STAT3/SLC7A11-regulator-1
  • HY-N14186
    Asperaldin
    		Inhibitor
    Asperaldin is a potent aldose reductase (RLAR) inhibitor found in Aspergillus niger CFR-1046.
    Asperaldin
  • HY-175639
    ALR2-IN-8
    		Inhibitor
    ALR2-IN-8 is a potent aldose reductase (ALR2/AKR1B1) inhibitor with a KI of 7.34 nM. ALR2-IN-8 has extremely low toxicity to normal cells and has a weak direct killing effect on cancer cells. ALR2-IN-8 can used for the studies of diabetic and inflammation-linked disorders.
    ALR2-IN-8
  • HY-149254
    PTP1B/AKR1B1-IN-1
    		Inhibitor
    PTP1B/AKR1B1-IN-1 is a dual inhibitor of protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), with IC50s of 0.06 μM and 4.3 μM, respectively. PTP1B/AKR1B1-IN-1 also inhibits TC-PTP with an IC50 value of 9 μM. PTP1B/AKR1B1-IN-1 serves as an insulin-mimetic agent in murine myoblasts, and reduces AKR1B1-dependent sorbitol accumulation. PTP1B/AKR1B1-IN-1 inhibits development of type 2 diabetes mellitus (T2DM) to control blood glucose levels.
    PTP1B/AKR1B1-IN-1
  • HY-121933
    IDD388
    		Inhibitor 99.40%
    IDD388 is a selective aldose reductase (ALR2) inhibitor with an IC50 of 30 nM. IDD388 displays selectivity for ALR2 over ALR1 (IC50 of 14 μM).
    IDD388
Cat. No. Product Name / Synonyms Application Reactivity